Month: August 2024

The perioperative treatment of early-stage non-small cell lung cancer (NSCLC) has now entered the era of precision-targeted therapy and immunotherapy. At the NSCLC Medical Treatment Session of the International Lung Cancer Conference (CLC 2024) held from August 9-11, Dr. Huijuan Wang from Henan Cancer Hospital delivered a keynote speech titled "Advances in Perioperative Treatment of NSCLC." This article provides a brief overview of the content of her presentation.

The exploration of biomarkers in immunotherapy is constantly evolving, yet only a few have proven to effectively guide clinical decision-making. At the 2024 International Lung Cancer Conference (CLC 2024), held from August 9-11, Dr. Panwen Tian from West China Hospital of Sichuan University delivered a keynote speech titled "Thoughts and Exploration of Biomarkers in Lung Cancer Immunotherapy." This article provides a brief overview of the report.

In recent years, the field of breast cancer treatment has witnessed a series of innovative research developments, particularly in the treatment of HER2+ early breast cancer (EBC). Strategies such as "de-escalation," "chemotherapy-free," and "precision treatment" have become hot topics. At the 7th Oncology Precision Diagnosis and Treatment Conference and the 10th Breast Cancer Individualized Treatment Conference (2024 COMB), Oncology Frontier invited Dr. Tao Sun from Liaoning Cancer Hospital to delve into the latest developments and future directions in the treatment of HER2+ EBC.

At the full-session management segment of the 7th Oncology Precision Diagnosis and Treatment Conference and the 10th Breast Cancer Individualized Treatment Conference (2024 COMB), Dr. Jiani Wang from the Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College, along with three other breast cancer experts, engaged in a deep discussion on the significance of the ADAPT study for HER2+ breast cancer treatment and how to manage patients throughout the treatment process. Following the conference, Oncology Frontier invited Dr. Jiani Wang to provide an in-depth analysis of the ADAPT study. She also shared the latest achievements of her team in the field of anti-HER2 treatment and her expectations for the treatment of HER2-positive breast cancer patients.